Literature DB >> 10957700

Plasma levels after peroral and topical ibuprofen and effects upon low pH-induced cutaneous and muscle pain.

A E Steen1, P W Reeh, G Geisslinger, K H Steen.   

Abstract

Cutaneous applications are gaining popularity in the treatment of cutaneous pain and of painful disorders in joints and muscle. The low pH-pain model in human skin has previously been able to demonstrate the effects of NSAIDs in dose-dependent manner and to establish time-effect relationships. We examined the analgesic action of ibuprofen after cutaneous application and compared the effects with oral administration. The two studies (with n = 12 subjects each) were performed in a double-blind, randomized fashion with a 1-week cross-over interval. In study 1 volunteers received intradermal infusions with phosphate buffered saline solution of pH 5.2 and received either 800 mg ibuprofen per os and topical placebo, or 4 g of a 5% commercial ibuprofen gel topically applied and oral placebo capsules, respectively. In study 2 the same protocol was applied with painful intramuscular infusion of stronger, isotonic phosphate buffer (pH 5.2). The flow rate of the pH-infusion was individually adjusted to induce pain with a magnitude of 20% on a visual analogue scale (ranging from 'no' (0%) to 'unbearable pain' (100%)). Ibuprofen (S-, R-) plasma levels after oral administrations were measured with HPLC, and after topical applications, by gas chromatography combined with mass spectroscopy to determine plasma levels in the range of ng/ml. In the cutaneous model pain ratings decreased to zero after topical verum gel within 45 min of the observation period of 55 min. Pain reduction after peroral ibuprofen was of the same magnitude, but was achieved within only 30 min. In the muscle model, the commercial ibuprofen gel did not reduce the pain in the acidic muscle. The peroral ibuprofen was less effective in the muscle compared to the skin pain model, although there was a significant progressive pain reduction within 55 min. Reasons for the differential susceptibility of cutaneous vs muscular acidosis pain to ibuprofen remain to be established. Copyright 2000 European Federation of Chapters of the International Association for the Study of Pain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10957700     DOI: 10.1053/eujp.2000.0173

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  6 in total

1.  Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.

Authors:  Clara Sciorati; Roberta Buono; Emanuele Azzoni; Silvana Casati; Pierangela Ciuffreda; Grazia D'Angelo; Dario Cattaneo; Silvia Brunelli; Emilio Clementi
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

2.  Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study.

Authors:  Reto Widrig; Andy Suter; Reinhard Saller; Jörg Melzer
Journal:  Rheumatol Int       Date:  2007-02-22       Impact factor: 2.631

3.  A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.

Authors:  Clara Sciorati; Daniela Miglietta; Roberta Buono; Viviana Pisa; Dario Cattaneo; Emanuele Azzoni; Silvia Brunelli; Emilio Clementi
Journal:  Pharmacol Res       Date:  2011-05-12       Impact factor: 7.658

4.  Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH.

Authors:  Sandra Holt; Christopher J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-20       Impact factor: 3.000

Review 5.  ASICs Mediate Pain and Inflammation in Musculoskeletal Diseases.

Authors:  Ramy E Abdelhamid; Kathleen A Sluka
Journal:  Physiology (Bethesda)       Date:  2015-11

Review 6.  Nobel somatosensations and pain.

Authors:  Peter W Reeh; Michael J M Fischer
Journal:  Pflugers Arch       Date:  2022-02-14       Impact factor: 3.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.